KDR and angiosarcoma: Conversely, the addition of bevacizumab or pazopanib to weekly paclitaxel failed to improve outcomes,25 suggesting that combinations involving anti‐VEGF agents should probably be further explored in more selected angiosarcoma subtypes (e.g., angiosarcoma with KDR mutations).